Literature DB >> 25907702

Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?

Eric M Ruderman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25907702     DOI： 10.1038/nrrheum.2015.58

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

Review 1.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  Do we really need five TNF antagonists?

Authors:  Eric M Ruderman
Journal:  Rheumatology (Oxford)       Date:  2010-02-19       Impact factor: 7.580

3.  Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Authors:  Mark C Genovese; Roy Fleischmann; Alan J Kivitz; Maria Rell-Bakalarska; Renata Martincova; Stefano Fiore; Patricia Rohane; Hubert van Hoogstraten; Anju Garg; Chunpeng Fan; Janet van Adelsberg; Steven P Weinstein; Neil M H Graham; Neil Stahl; George D Yancopoulos; Tom W J Huizinga; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

4.  A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.

Authors:  P Mease; V Strand; L Shalamberidze; A Dimic; T Raskina; Li-An Xu; Y Liu; J Smith
Journal:  Ann Rheum Dis       Date:  2012-02-10       Impact factor: 19.103

Review 5.  Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Authors:  Monika M Schoels; Désirée van der Heijde; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Miho M Murikama; Norihiro Nishimoto; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2012-11-10       Impact factor: 19.103

6.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103

7.  Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Authors:  Tom W J Huizinga; Roy M Fleischmann; Martine Jasson; Allen R Radin; Janet van Adelsberg; Stefano Fiore; Xiaohong Huang; George D Yancopoulos; Neil Stahl; Mark C Genovese
Journal:  Ann Rheum Dis       Date:  2013-12-02       Impact factor: 19.103

8.  Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Authors:  Mark C Genovese; Roy Fleischmann; Daniel Furst; Namieta Janssen; John Carter; Bhaskar Dasgupta; Judy Bryson; Benjamin Duncan; Wei Zhu; Costantino Pitzalis; Patrick Durez; Kosmas Kretsos
Journal:  Ann Rheum Dis       Date:  2014-03-18       Impact factor: 19.103

9.  Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

Authors:  Josef S Smolen; Michael E Weinblatt; Shihong Sheng; Yanli Zhuang; Benjamin Hsu
Journal:  Ann Rheum Dis       Date:  2014-04-03       Impact factor: 19.103
  9 in total
  4 in total

1.  Correlation of interleukin 6 and transforming growth factor β1 with peripheral blood regulatory T cells in rheumatoid arthritis patients: a potential biomarker.

Authors:  Majid Khoshmirsafa; Farhad Seif; Nader Bagheri; Pezhman Beshkar; Mohammad Mousavi; Hedayatollah Shirzad
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

2.  Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis.

Authors:  Hui Jiang; Fu-Rong Wu; Jian Liu; Xiu-Juan Qin; Nan-Nan Jiang; Wei-Ping Li
Journal:  Int J Mol Med       Date:  2019-07-22       Impact factor: 4.101

3.  Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.

Authors:  Lei Ma; Christine Xu; Anne Paccaly; Vanaja Kanamaluru
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

4.  Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.

Authors:  Anne J Paccaly; Pavel Kovalenko; Janie Parrino; Anita Boyapati; Christine Xu; Hubert van Hoogstraten; Tomonori Ishii; John D Davis; A Thomas DiCioccio
Journal:  J Clin Pharmacol       Date:  2020-07-29       Impact factor: 3.126
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.